Lakefront Biotherapeutics N.V. (LKFT)
LKFT Stock Price Chart
Explore Lakefront Biotherapeutics N.V. interactive price chart. Choose custom timeframes to analyze LKFT price movements and trends.
LKFT Company Profile
Discover essential business fundamentals and corporate details for Lakefront Biotherapeutics N.V. (LKFT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 May 2005
Employees
452.00
Website
https://lakefrontbio.comCEO
Henry O. Gosebruch
Description
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
LKFT Financial Timeline
Browse a chronological timeline of Lakefront Biotherapeutics N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.82, while revenue estimate is $6.20m.
Earnings released on 6 May 2026
EPS came in at $0.25 surpassing the estimated -$0.94 by +126.21%, while revenue for the quarter reached $7.63m , missing expectations by -20.43%.
Earnings released on 23 Feb 2026
EPS came in at $13.90 surpassing the estimated -$0.13 by +11.08k%, while revenue for the quarter reached $1.05bn , beating expectations by +1.17k%.
Earnings released on 5 Nov 2025
EPS came in at -$3.54 falling short of the estimated -$0.48 by -641.43%, while revenue for the quarter reached $82.12m , beating expectations by +7.90%.
Earnings released on 23 Jul 2025
EPS came in at -$1.85 falling short of the estimated -$0.23 by -711.81%, while revenue for the quarter reached $76.82m , missing expectations by -4.06%.
Earnings released on 23 Apr 2025
EPS came in at -$2.67 falling short of the estimated -$0.14 by -1.78k%, while revenue for the quarter reached $85.28m , beating expectations by +18.60%.
LKFT Stock Performance
Access detailed LKFT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
